Dr. Daver on CAR T-Cell Therapy Approval in Pediatric ALL
November 16th 2017Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the approval of a chimeric antigen receptor (CAR) T-cell therapy in pediatric acute lymphoblastic leukemia.
Read More
Dr. Daver on Immune Checkpoint Pathways in AML
December 28th 2016Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses research evaluating different immune checkpoint pathways in patients with acute myeloid leukemia.
Read More
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management
TERZO Trial Seeks to Validate Duvelisib as an Effective Targeted Treatment in TFH Nodal T-Cell Lymphoma
Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC
Kimberly Stegmaier Named as Pediatric Oncology Chair at Dana-Farber
2 Commerce Drive
Cranbury, NJ 08512